Company Overview and News

 
LGI Homes Opens New Section in Highly Sought After North Austin Community

19h globenewswire
JARRELL, Texas, Oct. 19, 2018 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (Nasdaq:LGIH) announces the opening of a new section and lot offering in the community of Sonterra, located in the highly desirable North Austin corridor.
LGIH

 
LGIH / LGI Homes, Inc. null

2018-10-13 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,U M-38O3R Q,2]%(#(X,S([email protected],B]4(#,S,[email protected]@6R [email protected],30Y73X^#65N M9&]B:@[email protected](" @(" @(" @(" @(" @(" @#0HQ-B P(&]B:@T\/"]$96-O9&50 M87)M7!E+UA2968O5ULQ(#(@,5T^/G-T('$URH&)D:&&2 E#(Q,_QEW_P<(, "1G [email protected] M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HQ.2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X,R],96YG [email protected]@-S O4R T.
LGIH

 
LGIH / LGI Homes, Inc. null

2018-10-13 sec.gov
Document
LGIH

 
LGIH / LGI Homes, Inc. null

2018-10-13 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,T M-C4O3R Q,2]%(#(X,[email protected],B]4(#,S,[email protected]@6R [email protected],30Y73X^#65N M9&]B:@[email protected](" @(" @(" @(" @(" @(" @#0HQ-B P(&]B:@T\/"]$96-O9&50 M87)M7!E+UA2968O5ULQ(#(@,5T^/G-T('$UP,,3(P,,T!*&!B9_C/[email protected]\08 ".X [email protected] M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HQ.2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X,R],96YG [email protected]@-S O4R T.
LGIH

 
LGIH / LGI Homes, Inc. null

2018-10-13 sec.gov
Document
LGIH

 
LGIH / LGI Homes, Inc. null

2018-10-13 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S$X M.3DO3R [email protected],C
LGIH

 
LGI Homes, Inc. Reports September and Third Quarter 2018 Home Closings and 2018 Third Quarter Earnings Conference Call

2018-10-03 globenewswire
THE WOODLANDS, Texas, Oct. 03, 2018 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (Nasdaq:LGIH) today announced 478 homes closed in September 2018, compared to 542 home closings in September 2017. In addition, the Company announced quarterly home closings of 1,601 for the third quarter of 2018 compared to 1,729 home closings in the third quarter of 2017. The Company finished the first nine months of 2018 with 4,660 home closings, a 16.
LGIH

 
Story Stocks: Lennar hits news lows after new orders disappoint (LEN)

2018-10-03 briefing
The Briefing.com RSS (really simple syndication) service is a method by which we offer story headline feeds in XML format to readers of the Briefing.com web site who use RSS aggregators. By using Briefing.com’s RSS service you agree to be bound by these Terms of Use. If you do not agree to the terms and conditions contained in these Terms of Use, we do not consent to provide you with an RSS feed and you should not make use of Briefing.
TOL LGIH

2
Are Fears Overblown on Homebuilders’ Stocks?

2018-09-26 247wallst - 2
Following a strong performance in 2017, U.S. homebuilders have had a disappointing first nine months of 2018. Looking at a group of seven stocks, the best performer of the bunch so far this year is down nearly 16%.
MTH TOL DHI LGIH LEN PHM NVR LEN.B

 
Home-builder stocks are beaten down, but analysts are super-bullish on ‘super-affordable’

2018-09-24 marketwatch
In late July, D.R. Horton, Inc. DHI, -1.00% , announced third-quarter results that beat estimates, and offered stronger guidance for the coming quarters. Net income, sales orders, and home closings were all higher by double digits, management said, citing a set of market conditions that could only be described as a housing sweet spot: “healthy market conditions across most of our markets with solid demand… and the supply of new homes remains limited.
MTH LGIH NVR

1
The Ratings Game: Home builders hit new lows for the year after handful of downgrades

2018-09-21 marketwatch
Rising home inventory, declining profitability as the housing market slows should keep a lid on home builder stocks, analyst says
CCS MTH LGIH LEN LEN.B BZH BZMD

 
LGI Homes, Inc. Reports August 2018 Home Closings

2018-09-06 globenewswire
THE WOODLANDS, Texas, Sept. 06, 2018 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (Nasdaq:LGIH) today announced 585 homes closed in August 2018, compared to 596 home closings in August 2017. The Company ended the first eight months of 2018 with 4,182 home closings, a 20.9% increase over 3,459 home closings during the first eight months of 2017.
LGIH

3
9 Housing Stocks to Buy

2018-08-31 investorplace - 1
The U.S. economy looks like it’s getting stronger. Just this week, the GDP for last quarter was adjusted upward to 4.2% for the quarter. That almost doubled GDP in Q1.
CCS SKY CVCO LGIH LEN DHI PHM MDC CHCI LEN.B

6
Homebuilders: Signs Of Softness

2018-08-27 seekingalpha - 1
Homebuilding isn’t as easy as it used to be. After surging in 2017, homebuilders have slumped this year on concerns over a slowdown in the post-recession housing recovery.
KBH TOL DHI LEN PHM LGIH MDC AVHI

 
LGIH / LGI Homes, Inc. FORM S-3ASR

2018-08-24 sec.gov
TABLE OF CONTENTS As filed
LGIH

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 50187T106